Company / Cash & Equivalents
Arbutus Biopharma Corp Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$18.0M
FY2025
5-year range
$18.0M / $109.3M
FY2021-FY2025
Trend
-50.4%
vs FY2024
Sector context
#200 of 207
Health Care
What the data says
Among 207 Health Care companies, Arbutus Biopharma Corp is in the bottom 3% for cash & equivalents. Cash & Equivalents has fluctuated over the past 10 years, ranging from $18M in FY2025 to $109M in FY2021.
Based on SEC 10-K filings.
$18M in FY2025 with a 5-year CAGR of -19.2%.
Declined from $26M to $18M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -16.4%
- 5-Year CAGR
- -19.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 207This company $18.0M Sector average $669.5M
▼
-97.3% below sector average
Key checks
Key Insights
- 5-year CAGR of -19.2%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 50.4% year-over-year.
- Ranks #200 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $18.0M | -50.4% |
| FY2024 | $36.3M | +38.2% |
| FY2023 | $26.3M | -14.6% |
| FY2022 | $30.8M | -71.8% |
| FY2021 | $109.3M | +109.1% |
| FY2020 | $52.3M | +64.3% |
| FY2019 | $31.8M | -41.4% |
| FY2018 | $54.3M | +0.0% |
| FY2017 | $54.3M | +131.9% |
| FY2016 | $23.4M | -86.0% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026